immunocard STAT! C. difficile GDH-AB

Improves decision making for physicians by providing a convenient and timely result for toxigenic *C. difficile* in patients.

Minimize The Impact of C. difficile

Clostridium difficile is a major cause of health care-associated infections and detection is critical for improved decision making for patient care and infection control. Decreasing length of stay and unnecessary isolations can be a challenge for many hospitals.

The Immunocard STAT![®] *C. difficile* GDH-AB rapid assay from Meridian Bioscience helps you to deliver results to physicians with confidence.

- High NPV of antigen when combined with the direct detection of the Toxins, allows laboratories to quickly report reliable results.
- Provide confidence and peace of mind to physicians with results in less than 20 minutes to improve patient management decisions.

Is your lab currently adhering to the international guidelines^{1,2} for *Clostridium difficile* testing and diagnosis?

- International guidelines recommend different testing approaches for the laboratory detection of toxigenic *C. difficile*, including different combinations of GDH, Toxins and NAAT assays.
- One of the recommended testing algorithms is the combined approach for the simultaneous and direct detection of GDH and Toxins in stools.





Results that Matter

- Immunocard STAT! *C. difficile* GDH-AB is a one-step solution for your GDH and Toxin testing with simultaneous results in only 15 minutes.
- This test can be used as a standalone or algorithmic approach for your laboratory's *C. difficile* testing protocols.

Improving Outcomes with Actionable Results

- Improve decision making for physicians and infection control, whilst providing peace of mind for patients by avoiding unnecessary isolations.
- Save your laboratory time and money by utilizing a one-step solution for GDH and Toxin testing.

Product Specifications

Intended Use

Immunocard STAT! *C. difficile* GDH-AB is a rapid, qualitative, immunochromatographic assay for the simultaneous detection of *Clostridium difficile* Glutamate Dehydrogenase antigen and *Clostridium difficile* Toxins A and B in human stools.

Turnaround Time

< 20 minutes

Sample Type

Fresh untreated stool specimen

Sample Storage

- Refrigerated at 2°C 8°C up to 2 days.
- Frozen at \leq -20°C for longer periods.

Kit Storage

Kit should be stored at 2 - 30° C

Performance *vs commercially available assays		
	GDH	Toxins
Sensitivity*	95%	94.6%
Specificity*	99%	100%

Catalogue Number

Immunocard STAT![®] C. difficile GDH-AB (20 Tests) - 750520

Immunocard STAT!^{*} *C. difficile* GDH-AB External Controls (3 Pos + 3 Neg) - 750501



References

- European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. Crobach et al (2016). Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63-81
 Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), McDonald et al (2018). Clinical Infectious Diseases, Volume 66,
- Issue 7, 19 March 2018, Pages e1-e48 3. Immunocard STAT! *C. difficile* GDH-AB Package Insert, SN750520IFU

Ready to minimise the impact of *C. difficile* testing? Let's talk.

Contact a specialist at info@meridianbioscience.eu meridianbioscience.com/eu

